

Supplemental Table S1. Reported *in vitro* isoform specificities of PI3K inhibitors. The IC<sub>50</sub> (nM) reported in the literature for each PI3K inhibitor against Class IA catalytic isoforms in *in vitro* binding assays is shown. The source for each data set is listed. A66-(S) is termed a p110 $\alpha$ -specific inhibitor, AZD-6482 is classified as a p110 $\beta$ -specific inhibitor, and CAL-101 shows selectivity for p110 $\delta$ . GDC-0941 does not show significant isoform selectivity.

Reported *in vitro* IC<sub>50</sub> (nM)

Drug	p110 $\alpha$	p110 $\beta$	p110 $\delta$	Source
A66-(S)	32	>12500	>1250	Jamieson et. al. 2011
AZD-6482	1200	21	80	Nylander et. al. 2012
CAL-101	820	565	2.5	Lannutti et. al. 2010
GDC-0941	3	33	3	Folkes et. al. 2008